Glutathione is used across supplement, compounded, and clinic settings, but there is no approved consumer dosing standard for the uses people search for. The oral and topical figures below come from published trials; the injectable and IV figures are commonly cited, not a validated standard. Injectable and IV use involve sterile technique and belong with a qualified clinician.
Which doses have trials behind them
Glutathione is unusual among compounds on this site in that a real dose actually exists in the literature — and it is oral, small, and modest in effect. What does not exist is a validated injectable or intravenous amount, despite those being the forms most commonly sold for cosmetic use. Sorting the two apart is the substance of this page.
The studied doses, by route
A 2025 systematic review in the International Journal of Dermatology (PMID 39444151) pooled the skin-lightening and melasma literature and reported the doses that had been tested:
- Oral — 250 mg once daily, 250 mg twice daily, and 500 mg once daily all produced significant melanin-index reductions versus placebo across multiple randomized trials.
- Topical — 0.5% was significantly more effective than 0.1% and than placebo.
- Combination — topical plus oral outperformed either alone.
- Intravenous — one placebo-controlled study exists, and the reviewers concluded that "IV glutathione is contraindicated due to lack of efficacy and side effects."
The core randomized trial underneath the oral figures used 250 mg/day for 12 weeks in a three-arm design comparing reduced glutathione, oxidized glutathione, and placebo in 60 enrolled participants, 57 completing (Weschawalit et al., 2017; PMC5413479). Its melanin-index effect reached significance only in subgroup analysis, and the reviewers describe results across this literature as unsustainable — they do not persist once dosing stops. A dose that works while you take it and reverses afterwards is a different proposition from a treatment.
The commonly cited injectable figures
Frequently cited patterns in cosmetic and clinic settings, which vary widely and are not supported by controlled trial data:
- Roughly 600–1,200 mg per injection or IV session, given intermittently — for example a few times per week — rather than daily.
- Escalating session amounts marketed for faster or more pronounced lightening.
- Liposomal and sublingual oral products, marketed to improve absorption, with variable supporting data.
These are reference figures describing what is offered, not validated doses. The route they belong to is the one three separate dermatology reviews advise against (PMID 39444151, PMID 27088927, PMID 30133125), the second of these noting that intravenous glutathione prompted regulatory warnings from the Philippine FDA.
Administration and bioavailability
Injectable glutathione is typically supplied as a powder requiring reconstitution with a sterile diluent before intramuscular or intravenous administration, with IV given in a clinical setting. Two mechanics govern what is actually delivered:
- Concentration is set by vial content relative to diluent volume added; syringe units measure volume, not milligrams.
- Bioavailability — the fraction reaching circulation intact — is the reason oral and injectable amounts are not interchangeable. Intact oral absorption of glutathione is limited, which is the stated rationale behind parenteral products in the first place.
That rationale is worth examining rather than accepting: the oral route, with its poor intact absorption, is the one that produced the positive randomized results, while the route designed to bypass that problem is the one the reviews reject.
Why oversight matters
Glutathione is sold in the United States as a dietary supplement and is not an FDA-approved drug for antioxidant, anti-aging, or skin-lightening indications, so there is no labeled dose or monitoring standard. Injection and infusion add sterility, technique, and monitoring requirements that no calculator addresses, and compounded or gray-market vials carry no purity or sterility assurance. A clinician is the right party to judge whether any of this is appropriate at all — a prior question to how much.